Figures & data
Figure 1 Interleukin-6 activates a number of key inflammatory pathways.
![Figure 1 Interleukin-6 activates a number of key inflammatory pathways.](/cms/asset/71c63a81-ce23-4c6c-b0af-4c63e8c6bc31/dppa_a_41433_f0001_c.jpg)
Figure 2 Interleukin-6 signal transduction and blockage by tocilizumab.Reprinted from Biologics, volume 2, Okuda Y, Review of tocilizumab in the treatment of rheumatoid arthritis, pages 75–82, Copyright © 2008, with permission from Dove.Citation26
![Figure 2 Interleukin-6 signal transduction and blockage by tocilizumab.Reprinted from Biologics, volume 2, Okuda Y, Review of tocilizumab in the treatment of rheumatoid arthritis, pages 75–82, Copyright © 2008, with permission from Dove.Citation26](/cms/asset/225ff034-1840-446f-82d7-ea347c7ed0f9/dppa_a_41433_f0002_c.jpg)
Table 1 Key trials of tocilizumab
Table 2 Clinical efficacy in Phase III trials
Table 3 Changes in fatigue, pain and disability in key trials
Table 4 Adverse events in Phase III trials